"He who is greedy for gain troubles his own house,
But he who hates bribes will live."
Proverbs 15:27
[Author's Note: We've had our issues with the UT open records process over the years, but in this case they responded within three business days with this very helpful list and we want to commend and thank them for doing so while avoiding the Attorney General process.]
Following our post last week about the UT "venture fund" we submitted several related open records requests to the system; they began to reply yesterday with this summary of the disbursements:
It will take us awhile to go through all the companies that received funds, but if readers want to help save time and by crowd-sourcing this project they are welcome to look into the entities listed in the "company" column and they can e-mail us anything they discover at cahnman@hotmail.com.
UTHF portfolio summary 7-Jun-16 Company Originating UT Institution Investment Date Amount Invested Investment Round Investment Vehicle Cerevast Therapeutics UTHSC-H Aug-12 $100,007 Series C Preferred Stock Latakoo UTSA Oct-12 $200,000 Note Convertible Note FibeRio UTPA Nov-12 $999,999 Series C Preferred Stock Apollo Endosurgery UTMB Dec-12 $999,999 Series B Preferred Stock Rapamycin Holdings UTHSC-SA Dec-12 $250,000 Seed Common Stock Cardiovate UTSA Jan-13 $50,000 Note Convertible Note M-87 UTAUS Jan-13 $500,000 Note Convertible Note PLx UTHSC-H Jan-13 $400,000 Series G Preferred Stock MicroTransponder UTD May-13 $336,370 Series B-1 Preferred Stock Lung Therapeutics UTHSC-T Jul-13 $300 Pre-Seed Common & Preferred Stock Rapamycin Holdings UTHSC-SA Jul-13 $121,976 Seed Convertible Note EMIT Corporation UTHSC-H Sep-13 $430,000 Series A Preferred Stock Lung Therapeutics UTHSC-T Sep-13 $100,000 Note tranche Convertible Note M-87 UTAUS Dec-13 $200,000 Series A Preferred Stock Lynx Labs UTAUS Mar-14 $100,000 Note Convertible Note Lung Therapeutics UTHSC-T Apr-14 $100,000 Note tranche Convertible Note Molecular Match UTMDACC Jul-14 $593,767 Series A Preferred Stock Aeglea BioTherapeutics UTAUS Jul-14 $1,000,000 Series A Preferred Stock Apollo Endosurgery UTMB Aug-14 $1,499,999 Series C Preferred Stock Lung Therapeutics UTHSC-T Sep-14 $100,000 Note tranche Convertible Note Lung Therapeutics UTHSC-T Jan-15 $100,000 Note tranche Preferred Stock M-87 UTHSC-T Feb-15 $594,635 Series B Convertible Note Aeglea BioTherapeutics UTHSC-T Mar-15 $1,200,000 Series B Preferred Stock Decisio Health UTHSC-H May-15 $475,000 Note Convertible Note Admittance Technologies UTHSC-SA Jun-15 $224,999 Series A Preferred Stock FibeRio UTPA Jul-15 $170,000 Series A-1 Preferred Stock Lung Therapeutics UTHSC-T Aug-15 $100,000 Note tranche Preferred Stock Apollo Endosurgery UTMB Sep-15 $350,909 Bridge Convertible Note MicroTransponder UTD Oct-15 $311,318 Series C Preferred Stock Alafair Biosciences UTAUS Feb-16 $399,998 Series A/A-1 Preferred Stock Aeglea BioTherapeutics UTAUS Apr-16 $2,000,000 IPO Common Stock Decisio Health UTHSC-H Apr-16 $538,723 Series A-2 Preferred Stock Lung Therapeutics UTHSC-T Apr-16 $249,999 Series B Preferred Stock Accordion Health UTAUS May-16 $100,000 Seed Convertible Note Total $14,897,998
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.